Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.
Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.